Enanta Pharma (ENTA) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
August 7, 2018 4:01 PM EDTWebcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $57.3 million, a quarter-to-quarter increase of 30% Net income was $20.3 million, or $0.97 per diluted common share Preliminary Phase 1 results demonstrate that RSV candidate EDP-938 was generally safe and well tolerated and support its progression to Phase 2 Cash and marketable securities totaled $295.5 million at June 30, 2018
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a... More
